Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

NCT01996696 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Results of interim analysis indicate no statistically significant difference in the primary objective between the two arms at baseline and 12 months of follow-up.

Conditions

Prostatic Neoplasm

Interventions

DRUG: Metformin
DRUG: Placebo

Sponsor

AHS Cancer Control Alberta